Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement

Growth hormone (GH) has been used for over 35 years, and its safety and efficacy has been studied extensively. Experimental studies showing the permissive role of GH/insulin-like growth factor 1 (IGF-I) in carcinogenesis have raised concerns regarding the safety of GH replacement in children and adults who have received treatment for cancer and those with intracranial and pituitary tumours. A consensus statement was produced to guide decision-making on GH replacement in children and adult survivors of cancer, in those treated for intracranial and pituitary tumours and in patients with increased cancer risk. With the support of the European Society of Endocrinology, the Growth Hormone Research Society convened a Workshop, where 55 international key opinion leaders representing 10 professional societies were invited to participate. This consensus statement utilized: (1) a critical review paper produced before the Workshop, (2) five plenary talks, (3) evidence-based comments from four breakout groups, and (4) discussions during report-back sessions. Current evidence reviewed from the proceedings from the Workshop does not support an association between GH replacement and primary tumour or cancer recurrence. The effect of GH replacement on secondary neoplasia risk is minor compared to host- and tumour treatment-related factors. There is no evidence for an association between GH replacement and increased mortality from cancer amongst GH-deficient childhood cancer survivors. Patients with pituitary tumour or craniopharyngioma remnants receiving GH replacement do not need to be treated or monitored differently than those not receiving GH. GH replacement might be considered in GH-deficient adult cancer survivors in remission after careful individual risk/benefit analysis. In children with cancer predisposition syndromes, GH treatment is generally contraindicated but may be considered cautiously in select patients.

[1]  G. Johannsson,et al.  Growth hormone deficiency in adults with hypopituitarism—What are the risks and can they be eliminated by therapy? , 2021, Journal of internal medicine.

[2]  R. Allodji,et al.  Influence of growth hormone therapy on the occurrence of a second neoplasm in survivors of childhood cancer , 2021, Yearbook of Paediatric Endocrinology.

[3]  G. Johannsson,et al.  Incidence of Benign and Malignant Tumors in Patients with Acromegaly is Increased: a Nationwide Population-Based Study. , 2021, The Journal of clinical endocrinology and metabolism.

[4]  C. Boguszewski,et al.  Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors—a review of research and clinical practice , 2021, Pituitary.

[5]  A. Brodbelt,et al.  The growth rate and clinical outcomes of radiation induced meningioma undergoing treatment or active monitoring , 2021, Journal of Neuro-Oncology.

[6]  C. Ronckers,et al.  Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. , 2021, The Lancet. Oncology.

[7]  D. Lantvit,et al.  Mammary Tumors Growing in the Absence of Growth Hormone are More Sensitive to Doxorubicin than Wild-type Tumors. , 2021, Endocrinology.

[8]  K. McElreavey,et al.  Pituitary stalk interruption syndrome is characterized by genetic heterogeneity , 2020, PloS one.

[9]  P. Chanson,et al.  Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. , 2020, Endocrine connections.

[10]  E. Davis,et al.  Growth Hormone Upregulates Mediators of Melanoma Drug Efflux and Epithelial-to-Mesenchymal Transition In Vitro and In Vivo , 2020, Cancers.

[11]  H. Werner,et al.  Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation , 2020, Cells.

[12]  R. Murray,et al.  Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs , 2020, Expert opinion on drug safety.

[13]  J. Guevara-Aguirre,et al.  Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador , 2020, Reviews in Endocrine and Metabolic Disorders.

[14]  F. de Vathaire,et al.  Risk Factors of Subsequent Central Nervous System Tumors after Childhood and Adolescent Cancers: Findings from the French Childhood Cancer Survivor Study , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[15]  H. Werner,et al.  Role of the GH-IGF1 system in progression of cancer , 2020, Molecular and Cellular Endocrinology.

[16]  A. Swerdlow,et al.  Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. , 2020, The lancet. Diabetes & endocrinology.

[17]  C. Dimopoulou,et al.  Thyroid and colorectal cancer screening in acromegaly patients: should it be different from that in the general population? , 2020, European journal of endocrinology.

[18]  C. Höybye,et al.  Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies , 2020, BMC Endocrine Disorders.

[19]  M. Losa,et al.  Growth Hormone Therapy does not increase the risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence. , 2020, The Journal of clinical endocrinology and metabolism.

[20]  T. Tominaga,et al.  Heterogeneity of Growth Hormone Receptor Expression in Craniopharyngioma - Implications for Surgical Strategy. , 2020, World neurosurgery.

[21]  S. Melmed,et al.  Growth hormone in the tumor microenvironment , 2019, Archives of endocrinology and metabolism.

[22]  Carmen L. Wilson,et al.  Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health Outcomes. , 2019, The Journal of clinical endocrinology and metabolism.

[23]  S. Radovick,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE. , 2019, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[24]  J. Kopchick,et al.  The effects of growth hormone on therapy resistance in cancer , 2019, Cancer drug resistance.

[25]  L. Cohen,et al.  Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective , 2019, Hormone Research in Paediatrics.

[26]  M. Maghnie,et al.  Accuracy and Limitations of the Growth Hormone (GH) Releasing Hormone-Arginine Retesting in Young Adults With Childhood-Onset GH Deficiency , 2019, Front. Endocrinol..

[27]  F. Couch,et al.  Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. , 2019, Blood.

[28]  J. Flanagan,et al.  Targeting growth hormone function: strategies and therapeutic applications , 2019, Signal Transduction and Targeted Therapy.

[29]  S. Melmed,et al.  Excess growth hormone suppresses DNA damage repair in epithelial cells. , 2019, JCI insight.

[30]  A. Dwivedi,et al.  Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2 , 2019, Experimental & Molecular Medicine.

[31]  Rakesh R. Patel,et al.  Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Boguszewski,et al.  Growth Hormone's Links to Cancer. , 2018, Endocrine reviews.

[33]  A. Swerdlow,et al.  Risk of Meningioma in European Patients Treated With Growth Hormone in Childhood: Results From the SAGhE Cohort , 2018, The Journal of clinical endocrinology and metabolism.

[34]  B. Hoeben,et al.  Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age , 2018, Neuro-oncology.

[35]  A. Moreira,et al.  Occurrence of neoplasms in individuals with congenital, severe GH deficiency from the Itabaianinha kindred. , 2018, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[36]  C. Boguszewski,et al.  Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. , 2018, European journal of endocrinology.

[37]  L. Cohen,et al.  Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline. , 2018, The Journal of clinical endocrinology and metabolism.

[38]  L. Cohen,et al.  GH Therapy in Childhood Cancer Survivors: A Systematic Review and Meta-Analysis , 2018, The Journal of clinical endocrinology and metabolism.

[39]  P. Chanson,et al.  Growth Hormone Research Society perspective on biomarkers of GH action in children and adults , 2018, Endocrine connections.

[40]  J. Kopchick,et al.  MECHANISMS IN ENDOCRINOLOGY: Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects? , 2018, European journal of endocrinology.

[41]  M. Maghnie,et al.  Growth Hormone Deficiency in the Transition Age. , 2018, Endocrine development.

[42]  T. Zhu,et al.  Tumour-Derived Human Growth Hormone As a Therapeutic Target in Oncology , 2017, Trends in Endocrinology & Metabolism.

[43]  M. Hauptmann,et al.  Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A. Swerdlow,et al.  Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study , 2017, The Journal of clinical endocrinology and metabolism.

[45]  C. Thompson,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Neuroendocrine surveillance and management of neurosurgical patients. , 2017, European journal of endocrinology.

[46]  Shiyong Wu,et al.  Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps , 2017, Hormones and Cancer.

[47]  R. Mekary,et al.  Comparison of Physiologic Growth Hormone Replacement Therapy to No Replacement on Craniopharyngioma Recurrence in Pediatric Patients , 2017, Journal of Neurological Surgery Part B: Skull Base.

[48]  G. Armstrong,et al.  Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015 , 2017, JAMA.

[49]  Z. Ungvari,et al.  The GH/IGF-1 axis in a critical period early in life determines cellular DNA repair capacity by altering transcriptional regulation of DNA repair-related genes: implications for the developmental origins of cancer , 2017, GeroScience.

[50]  C. Thompson,et al.  Neuroendocrine surveillance and management of neurosurgical patients , 2017 .

[51]  A. Tirosh,et al.  Complications of acromegaly: thyroid and colon , 2017, Pituitary.

[52]  K. Nichols,et al.  Introduction to cancer genetic susceptibility syndromes. , 2016, Hematology. American Society of Hematology. Education Program.

[53]  A. Ridley,et al.  Is there a role for IGF‐1 in the development of second primary cancers? , 2016, Cancer medicine.

[54]  M. Murad,et al.  Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[55]  C. Boguszewski,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited. , 2016, European journal of endocrinology.

[56]  H. Sørensen,et al.  Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. , 2016, European journal of endocrinology.

[57]  R. Arceci,et al.  Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia , 2016, Pediatric blood & cancer.

[58]  Timothy R. Smith,et al.  Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study. , 2016, Journal of neurosurgery. Pediatrics.

[59]  P. Chanson,et al.  Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations , 2016, European journal of endocrinology.

[60]  S. Melmed,et al.  Growth hormone is permissive for neoplastic colon growth , 2016, Proceedings of the National Academy of Sciences.

[61]  J. Bena,et al.  Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic–pituitary–adrenal axes in adults: results from a prospective randomized multicenter study , 2016, Pituitary.

[62]  D. Dunger,et al.  GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults , 2015, European journal of endocrinology.

[63]  Steve Harvey,et al.  Autocrine/paracrine roles of extrapituitary growth hormone and prolactin in health and disease: An overview. , 2015, General and comparative endocrinology.

[64]  L. Robison,et al.  Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study. , 2015, European journal of endocrinology.

[65]  C. Sklar,et al.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee. , 2015, The Journal of clinical endocrinology and metabolism.

[66]  M. Greene,et al.  Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes , 2015, British Journal of Cancer.

[67]  C. Pui,et al.  Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Noonan,et al.  The Efficacy and Safety of Growth Hormone Therapy in Children with Noonan Syndrome: A Review of the Evidence , 2014, Hormone Research in Paediatrics.

[69]  P. Sluss,et al.  Overweight/Obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency. , 2014, The Journal of clinical endocrinology and metabolism.

[70]  I. Gram,et al.  Insulin‐like growth factor I and risk of breast cancer by age and hormone receptor status—A prospective study within the EPIC cohort , 2014, International journal of cancer.

[71]  G. Armstrong,et al.  Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. , 2014, The Journal of clinical endocrinology and metabolism.

[72]  T. Key.  Nutrition, hormones and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[73]  D. Leroith,et al.  Insulin and IGFs in Obesity-Related Breast Cancer , 2013, Journal of Mammary Gland Biology and Neoplasia.

[74]  V. Anisimov,et al.  The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. , 2013, Critical reviews in oncology/hematology.

[75]  S. Melmed,et al.  Growth hormone is a cellular senescence target in pituitary and nonpituitary cells , 2013, Proceedings of the National Academy of Sciences.

[76]  A. Wagner,et al.  Bloom syndrome in short children born small for gestational age: a challenging diagnosis. , 2013, The Journal of clinical endocrinology and metabolism.

[77]  N. Sachdeva,et al.  Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF‐1 axis , 2013, Pediatric blood & cancer.

[78]  P. Nathan,et al.  Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review. , 2013, The Lancet. Oncology.

[79]  L. Robison,et al.  Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. , 2013, European journal of endocrinology.

[80]  C. You,et al.  Craniopharyngioma cell growth is promoted by growth hormone (GH) and is inhibited by tamoxifen: Involvement of growth hormone receptor (GHR) and IGF-1 receptor (IGF-1R) , 2013, Journal of Clinical Neuroscience.

[81]  Brenda J. Crowe,et al.  Prospective Safety Surveillance of GH-Deficient Adults: Comparison of GH-Treated vs Untreated Patients , 2013, The Journal of clinical endocrinology and metabolism.

[82]  A. V. D. van den Ouweland,et al.  Patient with a neurofibromatosis type 1 mutation but a clinical diagnosis of Noonan syndrome , 2012, Clinical dysmorphology.

[83]  F. Clavel-Chapelon,et al.  Dietary glycemic index and glycemic load and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). , 2012, The American journal of clinical nutrition.

[84]  M. Buchfelder,et al.  Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. , 2012, European journal of endocrinology.

[85]  D. Cook,et al.  A review of guidelines for use of growth hormone in pediatric and transition patients , 2012, Pituitary.

[86]  H. Delemarre-van de Waal,et al.  Effects of Growth Hormone Therapy on Bone Mass, Metabolic Balance, and Well-Being in Young Adult Survivors of Childhood Acute Lymphoblastic Leukemia , 2011, Journal of pediatric hematology/oncology.

[87]  M. Scholz,et al.  Harmonization of growth hormone measurements with different immunoassays by data adjustment , 2011, Clinical chemistry and laboratory medicine.

[88]  G. Brabant,et al.  Long-term safety of growth hormone replacement after CNS irradiation. , 2011, The Journal of clinical endocrinology and metabolism.

[89]  O. Dekkers,et al.  Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. , 2011, The Journal of clinical endocrinology and metabolism.

[90]  Z. Laron,et al.  Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. , 2011, European journal of endocrinology.

[91]  Federica Madia,et al.  Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans , 2011, Science Translational Medicine.

[92]  I. Gram,et al.  A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2011, Annals of human biology.

[93]  P. Clayton,et al.  Growth hormone, the insulin-like growth factor axis, insulin and cancer risk , 2011, Nature Reviews Endocrinology.

[94]  I. Blümcke,et al.  Hormone Receptor Expression in Craniopharyngiomas: A Clinicopathological Correlation , 2010, Neurosurgery.

[95]  J. Björk,et al.  Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. , 2010, The Journal of clinical endocrinology and metabolism.

[96]  Peter Kraft,et al.  Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. , 2010, Cancer research.

[97]  R. Lorini,et al.  Reassessment of the growth hormone status in young adults with childhood-onset growth hormone deficiency: reappraisal of insulin tolerance testing. , 2009, The Journal of clinical endocrinology and metabolism.

[98]  M. Buchfelder,et al.  Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. , 2009, European journal of endocrinology.

[99]  M. Vance,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. , 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[100]  N. Karavitaki,et al.  GH replacement in patients with non‐functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence , 2009, Clinical endocrinology.

[101]  J. Deijen,et al.  The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study , 2008, BMC pediatrics.

[102]  R. Mehta,et al.  Advanced rat mammary cancers are growth hormone dependent. , 2007, Endocrinology.

[103]  K. Ho,et al.  Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II : a statement of the GH Research Society in association with the European Society for Pediatric , 2007 .

[104]  F. Darendeliler,et al.  Recurrence of brain tumours in patients treated with growth hormone: Analysis of KIGS (Pfizer International Growth Database) , 2006, Acta paediatrica.

[105]  W. Shi,et al.  Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. , 2006, The Journal of clinical endocrinology and metabolism.

[106]  F Berrino,et al.  IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). , 2006, Endocrine-related cancer.

[107]  J. Warner,et al.  GH replacement does not increase the risk of recurrence in patients with craniopharyngioma , 2006, Clinical endocrinology.

[108]  M. Vance,et al.  Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. , 2006, The Journal of clinical endocrinology and metabolism.

[109]  P. Clayton,et al.  Consensus statement on the management of the GH-treated adolescent in the transition to adult care. , 2005, European journal of endocrinology.

[110]  C. Pui,et al.  Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  L. Robison,et al.  Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. , 2002, The Journal of clinical endocrinology and metabolism.

[112]  Brenda J. Crowe,et al.  Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? , 2002, The Journal of clinical endocrinology and metabolism.

[113]  C. Sainte-Rose,et al.  GH deficiency caused by cranial irradiation during childhood: factors and markers in young adults. , 2001, The Journal of clinical endocrinology and metabolism.

[114]  B. Brennan,et al.  The impact of irradiation on growth hormone responsiveness to provocative agents is stimulus dependent: results in 161 individuals with radiation damage to the somatotropic axis. , 2001, The Journal of clinical endocrinology and metabolism.

[115]  J. Wisoff,et al.  Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  E. Arvat,et al.  Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test. , 2000, The Journal of clinical endocrinology and metabolism.

[117]  B. Bengtsson,et al.  GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety , 1999, Clinical endocrinology.

[118]  M. Maghnie,et al.  Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. , 1999, The Journal of clinical endocrinology and metabolism.

[119]  M. Ranke,et al.  Efficacy and Safety of Growth Hormone Treatment in Children with Prior Craniopharyngioma: An Analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996 , 1998, Hormone Research in Paediatrics.

[120]  F Vignon,et al.  [Growth factors and cancer]. , 1994, Journal de gynecologie, obstetrique et biologie de la reproduction.

[121]  W. Ryder,et al.  Growth hormone and tumour recurrence. , 1992, BMJ.

[122]  P. Sönksen,et al.  The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. , 1989, The New England journal of medicine.

[123]  S. Shalet,et al.  EFFECT OF SPINAL IRRADIATION ON GROWTH , 1986, Pediatric Research.

[124]  P. A. Lee,et al.  Growth hormone therapy and tumor recurrence. Findings in children with brain neoplasms and hypopituitarism. , 1985, American journal of diseases of children.

[125]  Anita B. Roberts,et al.  Autocrine growth factors and cancer , 1985, Nature.

[126]  J. Roth,et al.  Hypoglycemia: A Potent Stimulus to Secretion of Growth Hormone , 1963, Science.